The SCMs reached a high consensus for the statement on determining BRCA status of HER2-negative eBC patients before surgery to influence surgical decisions; discussing contralateral risk-reducing mastectomy (CRRM) for women with BRCA pathogenic variants scheduled for therapeutic mastectomy; risk-reducing mastectomy (RRM) being an effective preventive measure for BRCA variant carriers; and considering breast-conserving surgery for BRCA carriers with primary BC (Statements 1 to 4, Table 1). Here, ERBB2 is linked to breast cancer.